Clinical Trials Browser

Neuroendocrine Tumors, Disease Progression

NCT07274384 2025-12-10

HYPERBOLIC

Phase 2 Not yet recruiting

74 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms, Disease Progression

NCT04974671 2025-12-04

Trial Of Stereotactic Body Radiation Therapy (SBRT) for Oligoprogression on Immune Checkpoint Inhibitors (ICI) in Metastatic Renal Cell Carcinoma

Phase 2 Recruiting

30 enrolled

Genitourinary

Carcinoma, Renal Cell, Disease Progression

NCT06472388 2024-06-25

EVENET

Phase 2 Recruiting

100 enrolled

EndocrineNET

Carcinoid Tumor, Adenoma, Islet Cell, Neuroendocrine Tumors, Disease Progression

NCT03374332 2024-02-08

Fractionated Gemtuzumab Ozogamicin Followed by Non-engraftment Donor Leukocyte Infusions for Relapsed/Refractory Acute Myeloid Leukemia

Phase 2 Active not recruiting

11 enrolled

Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute, Disease Progression

NCT04149821 2023-06-15

Umbralisib Plus Ublituximab (U2) in Progressive CLL After Novel Therapy

Phase 2 Terminated

1 enrolled 8 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell, Disease Progression

NCT04033432 2022-04-27

sEphB4-HSA in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

Phase 2 Unknown

14 enrolled 13 charts

Genitourinary

Prostatic Neoplasms, Disease Progression

NCT04905056 2021-05-27

A Prospective, Two-center, Single Arm Phase II Clinical Study to Evaluate Safety and Effectiveness of Ablation Therapy in the Treatment of Lung Cancer Presenting as Ground-glass Nodules

Phase 2 Recruiting

120 enrolled

Disease Progression

NCT02715297 2020-03-10

GlioCave/NOA17

Phase 2 Unknown

162 enrolled

CNS

Glioblastoma, Disease Progression

NCT02538432 2019-11-04

Phase II Trial of EP4 Receptor Antagonist, AAT-007 (RQ-07; CJ-023,423) in Advanced Solid Tumors

Phase 2 Withdrawn

BreastGenitourinaryThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Prostatic Neoplasms, Disease Progression

NCT03469804 2019-10-21

KAPKEY

Phase 2 Unknown

17 enrolled

Sarcoma

Sarcoma, Kaposi, Disease Progression

NCT01737450 2019-06-24

PIK-ORL

Phase 2 Completed

58 enrolled

Head & Neck

Head and Neck Neoplasms, Neoplasm Metastasis, Recurrence, Disease Progression

NCT00530140 2011-10-06

FLIDVAX2006

Phase 2 Unknown

100 enrolled

Lymphoid

Lymphoma, Follicular, Disease Progression

NCT00517621 2011-02-25

Use of FACT-GOG/NTX Questionnaire in Peripheral Neurotoxicity & Validation of a French Version of This Questionnaire

Phase 2 Completed

100 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms, Recurrence, Disease Progression

NCT00172367 2008-09-26

Chemoprevention Trial for Uremia-Associated Urothelial Carcinoma

Phase 2 Withdrawn

80 enrolled

Genitourinary

Carcinoma, Transitional Cell, Uremia, Disease Progression

Clinical Trials

ReLUTH

HYPERBOLIC

Trial Of Stereotactic Body Radiation Therapy (SBRT) for Oligoprogression on Immune Checkpoint Inhibitors (ICI) in Metastatic Renal Cell Carcinoma

EVENET

Fractionated Gemtuzumab Ozogamicin Followed by Non-engraftment Donor Leukocyte Infusions for Relapsed/Refractory Acute Myeloid Leukemia

Umbralisib Plus Ublituximab (U2) in Progressive CLL After Novel Therapy

sEphB4-HSA in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

A Prospective, Two-center, Single Arm Phase II Clinical Study to Evaluate Safety and Effectiveness of Ablation Therapy in the Treatment of Lung Cancer Presenting as Ground-glass Nodules

GlioCave/NOA17

Phase II Trial of EP4 Receptor Antagonist, AAT-007 (RQ-07; CJ-023,423) in Advanced Solid Tumors

KAPKEY

PIK-ORL

FLIDVAX2006

Use of FACT-GOG/NTX Questionnaire in Peripheral Neurotoxicity & Validation of a French Version of This Questionnaire

Chemoprevention Trial for Uremia-Associated Urothelial Carcinoma